Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSL1 | P33121 | 5/20 | 0.56 |
| ▸ | ACSL3 | O95573 | 1/20 | 0.55 |
| ▸ | ACSL6 | Q9UKU0 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26857799 | 0.89 | AKR1C3 (0.51) | ACSL1ACSL3ACSL6HRH1DGAT1 | |
| SCHEMBL661203 | 0.84 | DGAT1 (0.57) | ACSL1ACSL3ACSL6DGAT1EPHX2 | |
| SCHEMBL21525587 | 0.84 | ACSL1 (0.49) | ACSL1ACSL3ACSL6DGAT1EPHX2 | |
| SCHEMBL25184896 | 0.84 | POLB (0.51) | ACSL1ACSL3ACSL6DGAT1EPHX2 | |
| SCHEMBL10148092 | 0.84 | DGAT1 (0.57) | ACSL1ACSL3ACSL6DGAT1EPHX2 | |
| SCHEMBL25184897 | 0.84 | POLB (0.51) | ACSL1ACSL3ACSL6DGAT1EPHX2 | |
| SCHEMBL13255507 | 0.84 | ALDH1A1 (0.60) | ACSL1ACSL3ACSL6DGAT1EPHX2 | |
| SCHEMBL661202 | 0.84 | DGAT1 (0.57) | ACSL1ACSL3ACSL6DGAT1EPHX2 | |
| SCHEMBL29856 | 0.83 | HRH1 (0.71) | HRH1SLC6A4SLC6A2SLC6A3EPHX2 | |
| SCHEMBL795203 | 0.82 | SLC6A4 (0.52) | ACSL1ACSL3ACSL6HRH1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719605-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | GlaxoSmithKline Intellectual Property (No.4) Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| EP-4626865-A1 | CYCLIC PYRAZOLE DIAMIDE IRE1/XBP1S ACTIVATORS | Protego Biopharma, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| WO-2024246862-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LIMITED (GB) | 2024-12-05 | — | — | WO | disclosed |
| WO-2024118810-A1 | CYCLIC PYRAZOLE DIAMIDE IRE1/XBP1S ACTIVATORS | PROTEGO BIOPHARMA, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-7968550-B2 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7223788-B2 | therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| EP-1597228-A2 | SUBSTITUTED N-ARYLHETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
| WO-2004072025-A2 | SUBSTITUTED N-ARYLHETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | ACSL1 3183/4885ACSL3 2825/4885ACSL6 3604/4885 |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | CYP11B2, CYP11B1, NQO1 | ACSL1 3290/4885ACSL3 2373/4885ACSL6 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.